PT  - JOURNAL ARTICLE
AU  - Cai, Hugh Y.
AU  - Cai, Allison
TI  - SARS-CoV-2 spike protein gene variants with N501T and G142D mutation dominated infections in minks in the US
AID  - 10.1101/2021.03.18.21253734
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.18.21253734
4099  - http://medrxiv.org/content/early/2021/04/19/2021.03.18.21253734.short
4100  - http://medrxiv.org/content/early/2021/04/19/2021.03.18.21253734.full
AB  - Large number of minks were infected with SARS-CoV-2 virus containing the spike protein Y453F mutation in Europe, causing zoonosis concerns. To evaluate the genetic characteristics of the US and Canadian mink-derived SARS-CoV-2 sequences, we analyzed all animal-derived (977), all Canadian (19,529) and US (173,277) SARS-CoV-2 sequences deposited in GISAID from December 2019 to March 12, 2021, and identified 2 dominant novel variants, the N501T-G142D variant and N501T-G142D-F486L variant, in the US mink-derived SARS-CoV-2 sequences. These variants were not found in minks from Canada or other countries. The Y453F mutation was not identified in the mink-derive sequences in the US and Canada. The N501T mutation occurred two months earlier in the human than in the minks in the US, and the novel N501T-G142D variant and N501T-G142D-F486L variant were found in human prior to minks. The result of this study indicates that the novel variants may have evolved during human infection and then transmitted to mink populations in the US.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study was performed on SARS-CoV-2 genome sequences deposited in public database (GISAID). It is not a clinical trial.Funding StatementThe authors received no financial support for the research, authorship, and/or publication of this article. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed on publicly available SARS-CoV-2 genome sequences only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used in this study were available from the GISAID hCov-19 Database. GISAID sequences with N501T, G142D and F486L mutations are listed in Supplementary Tables. https://www.gisaid.org/